RELX H1 Growth Beats AI Fears|Analysts Still Cut Targets on the Same Print

The Sell-Off That Came Before the Proof

RELX and its data-and-legal-information peers were sold off hard just days before the company's own results landed. The trigger was not RELX's numbers at all, but the launch of a new AI legal productivity tool from Anthropic, built to handle contract review and compliance work that RELX's Legal division has long charged for. Investors read that launch as a direct threat to the pricing power behind Lexis and the rest of RELX's subscription tools, and they sold first and asked questions later.

When the first-half results actually arrived on 23 July 2026, they ran the opposite direction from the sell-off's premise. Group organic revenue rose 7%, adjusted operating margin expanded 70 basis points against an expected 20, and the Legal division accelerated to 10% growth while Scientific, Technical and Medical hit 6%. Chief executive Erik Engstrom said the evolution of AI was adding value to RELX's own products, not stripping it away. So the bottleneck this video resolves is not whether AI is disrupting RELX today — the print says it is not, yet. It is whether the market believes that will still be true next year, and that belief gap is what still separates an entry point from a value trap.

Same Print, Opposite Verdicts

Here is the conflict that makes this print worth stopping on. Deutsche Bank's Steve Liechti raised his target to 3,100 pence and called the AI worries overplayed, arguing rivals using large language models cannot easily replicate RELX's proprietary content and embedded data infrastructure. UBS agreed, describing first-half growth as AI-led organic acceleration and reiterating a 3,600 pence buy target. In the same reporting window, Bernstein cut its target to 3,450 pence, Barclays cut to 3,075 pence, and Morgan Stanley trimmed its sterling target by 390 pence. These are not stale, pre-results calls — they were issued against the identical set of first-half numbers the bulls used to argue the opposite case.

UBS's 3,600 pence target implies almost 47% upside from the last close of 2,451 pence, while Bernstein and Barclays sit only a few hundred pence above where the stock already trades. That is an unusually wide spread for banks looking at the same disclosed revenue and margin figures. For a holder, this is not a question of whether the business grew this half — it plainly did. It is a question of which camp's forward assumption about AI's slower, second-order effect on pricing power is the one the market will eventually adopt.

The Assumption Behind the Multiple

UBS analyst Jo Barnet-Lamb framed the real story precisely: RELX shares trade at 17.6 times forecast 2026 earnings, well below the company's own five-year average of 24.1 times. That gap did not appear because RELX's growth slowed — growth just accelerated. It appeared because the market priced in a future erosion of RELX's pricing power that has not yet shown up in a single reported division. The multiple is not measuring this half's results at all; it is measuring how much the market still distrusts next year's.

The assumption every bear price cut logically requires is this: a single strong half does not falsify a multi-year disruption thesis, because AI's effect on subscription pricing power may simply lag its effect on subscription volume. Barnet-Lamb himself conceded that even after calling the results reassuring, he still expects the wider AI overhang to weigh on the shares near-term — he is holding both the bull evidence and the bear caution in the same note. That tension is the real trade here: not whether RELX grew this half, but whether growth this half is evidence the threat was always overstated, or simply evidence the threat has not started compounding yet.

What Actually Settles This

RELX itself is not waiting for the market to decide. On the same day as the results, the company launched a new non-discretionary buyback tranche of £150 million, running through early September, as part of a £2.25 billion programme for the year. That is management putting its own balance sheet behind the reading that its business is not being eroded. But a buyback is a statement of management's conviction, not independent proof the bears are wrong — it does not by itself close the valuation gap.

The variable that actually discriminates between these two camps is not the next full-year result, which arrives too late to act on. It is the next quarterly trading update's divisional growth figures, specifically whether Legal holds or extends its 10% pace and Scientific, Technical and Medical holds its 6%. If that update shows both divisions still accelerating, the re-rating case strengthens and the 17.6-times multiple becomes the entry point UBS is describing. If either division's growth stalls or slows toward the group average, the bear camp's caution is vindicated and the current valuation gap was priced correctly all along. Holders and watchers alike should treat that next divisional growth print as the checkpoint before deciding anything further.